Tags » Kidney Cancer

I had a kidney tumor removed (partial nephrectomy) - was clear cell renal carcinoma limited to the kidney - grade 1 (2.4cm) but stage 4 (WHO/ISUP 4) with clean margins. Pathology said it had sarcomatoid differentiation (95% sarcomatoid element) and extensive necrosis, extreme nuclear pleomorphism, multinucleate giant cells and /or rhabdoid sarcomatoid differentiation. Adrenal gland not identified and regional lymph noded pnx (could not be assessed. Pt1a grade. 5 questions: 1. Because it was grade 4 my doctor is recommending full removal of the kidney in 6 weeks. Is that the recommended course of action - is it likely that recurrence would be at that kidney again and removal lessens my chance of recurrence? 2. Should I have a PET scan, brain scan, bone scan, etc now since it was grade 4? They are saying just a chest CT is required now? 3. Is my likelihood of recurrence or distant metastes high because it was grade 4 even though it was very small stage 1a? Lots of conflicting information? 4. If the tumor was removed am I considered disease free and now just need aggressive regular surveillance? 5. How would I know if there was microvascular invasion and is the necrosis and sarcomatoid indicators of a recurrance? I'm quite scared so thank you so much for answering my questions!

The questions that you ask are surgical questions and must be asked of a urologist.  I am a nephrologist and do not have any surgical expertise in regards to kidney cancers.   35 more words

Kidney-Related Health Questions

Signs And Symptoms of Prostate Cancer In NJ

The prostate gland relate to the reproductive system in human males. It is responsible for the production of most parts of semen that carries sperms. Walnut sized, it is present below bladder surrounding upper portion of urethra. 461 more words

What I'm doing for Rare Disease Day

Each and every day since 1897,  I tell anyone who will listen about Cushing’s.  I pass out a LOT Cushing’s business cards.

Adding to websites, blogs and more that I have maintained continuously since 2000 – at mostly my own expense. 203 more words


Exelixis to partner with BMS in immunotherapy cancer trials

San Francisco-based biotech Exelixis is to team with Bristol-Myers Squibb in a series of trials investigating its own drug combined with BMS’ Opdivo. 

Initially, the collaboration will test Exelixis’ Cabometyx (cabozantinib) – a small molecule inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) – in combination with either one of or both Opdivo and Yervoy – BMS’ two leading PD-1 inhibitors – in a phase 3 trial in kidney cancer. 142 more words


Kidney Cancer; One Year On

This time last year I was 32 and I had not long been told that, while doing a CT of my upper GI tract for stomach reasons, they’d found a mass on my right kidney. 1,796 more words

Physical Health